My reference to her was in relationship to her understanding if clinical trials and regulatory time lines. She and UCLA know what the data looks like from a clinical perspective ie immune responses and length of time on trial. Her MBA gives her a good idea about the processes leading up to and including insurance reimbursement and rates so I wild say she has a very well informed perspective. When she gets anxious then I get anxious even though you and I both agree that the data already looks good enough for approval. Dr. Linda Liau seems to have wanted approval for patient use back in 2015 after initial data had been looked at in blinded fashion but she knows the process and that the process needed to be changed. Best wishes.
Market Data 
Markets 
AI
